

# Rylaze™ (asparaginase Erwinia chrysanthemi (recombinant)-rywn) (Intramuscular)

Document Number: IC-0612

Last Review Date: 12/01/2022

Date of Origin: 08/03/2021

Dates Reviewed: 08/2021, 11/2021, 04/2022, 11/2022, 12/2022

## I. Length of Authorization

Coverage will be provided for 6 months and may be renewed.

## II. Dosing Limits

### A. Quantity Limit (max daily dose) [NDC Unit]:

- Rylaze 10 mg/0.5 mL solution in a single-dose vial: 25 vials per 7 days

### B. Max Units (per dose and over time) [HCPCS Unit]:

- 2,500 billable units (250 mg) per week

## III. Initial Approval Criteria <sup>1</sup>

Coverage is provided in the following conditions:

- Patient is at least 1 month of age; **AND**

### Universal Criteria <sup>1</sup>

- Patient must not have a history of serious pancreatitis, thrombosis, or hemorrhagic events with prior L-asparaginase therapy; **AND**
- Used as a component of multi-agent chemotherapy; **AND**

### Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) † Φ <sup>1-3,5</sup>

- Used as a substitute for E. coli-derived asparaginase (e.g., pegaspargase) in cases of hypersensitivity (e.g., systemic allergic reactions or anaphylaxis) §

#### § Definition of Hypersensitivity Reactions (CTCAE v5.0) <sup>7,8</sup>

##### Allergic Reaction

- Grade 1: Systemic intervention not indicated
- Grade 2: Oral intervention indicated
- Grade 3: Bronchospasm; hospitalization for clinical sequelae; IV intervention indicated
- Grade 4: Life-threatening consequences; urgent intervention indicated
- Grade 5: Death

##### Anaphylaxis

- Grade 1 or 2: N/A

<ul style="list-style-type: none"> <li>- Grade 3: Symptomatic bronchospasm, with or without urticaria; parenteral intervention indicated; allergy-related edema/angioedema; hypotension</li> <li>- Grade 4: Life-threatening consequences; urgent intervention indicated</li> <li>- Grade 5: Death</li> </ul>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

† FDA Approved Indication(s); ‡ Compendia recommended indication(s); Ⓞ Orphan Drug

**IV. Renewal Criteria <sup>1</sup>**

Coverage can be renewed based upon the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease stabilization or improvement as evidenced by a complete response [CR] (i.e., morphologic, cytogenetic or molecular complete response CR), complete hematologic response or a partial response by CBC, bone marrow cytogenetic analysis, QPCR, or FISH; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe hypersensitivity reactions including anaphylaxis, pancreatitis, thrombosis, hemorrhage, hepatotoxicity, etc.

**V. Dosage/Administration <sup>1</sup>**

Indication	Dose		
All Indications	When replacing a long-acting asparaginase product, there are two Rylaze regimens that can be used. <i>(See table below for duration of administration as a replacement therapy).</i> <ul style="list-style-type: none"> <li>• Rylaze 25 mg/m<sup>2</sup> administered intramuscularly every 48 hours; <b>OR</b></li> <li>• Rylaze 25 mg/m<sup>2</sup> administered intramuscularly on Monday and Wednesday morning, and 50 mg/m<sup>2</sup> on Friday afternoon (Administer the Friday afternoon dose 53 to 58 hours after the Wednesday morning dose (e.g., 8:00 am on Monday and Wednesday, and 1:00 pm to 6:00 pm on Friday))</li> </ul>		
	When RYLAZE is Administered:	Recommended Duration of RYLAZE to Replace Calaspargase Pegol Products	Recommended Duration of RYLAZE to Replace Pegaspargase Products
	25 mg/m <sup>2</sup> intramuscular every 48 hours	Replace one dose of calaspargase pegol products with 11 doses of RYLAZE	Replace one dose of pegaspargase products with 7 doses of RYLAZE
	25 mg/m <sup>2</sup> intramuscular on Monday morning and Wednesday morning, and 50 mg/m <sup>2</sup> intramuscular on Friday afternoon	Replace one dose of calaspargase pegol products with 9 doses of RYLAZE	Replace one dose of pegaspargase products with 6 doses of RYLAZE

## VI. Billing Code/Availability Information

### HCP/PCS Code:

- J9021 – Injection, asparaginase, recombinant, (rylaze), 0.1 mg; 1 billable unit = 0.1 mg

### NDC(s):

- Rylaze 10 mg/0.5 mL solution in a single-dose vial: 68727-0900-xx

## VII. References

1. Rylaze [package insert]. Palo Alto, CA; Jazz Pharmaceuticals, Inc.; November 2022. Accessed November 2022.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Asparaginase *Erwinia chrysanthemi* (recombinant)-rywn. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed October 2022.
3. Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on *Erwinia* asparaginase. *Cancer*. 2011 Jan 15; 117(2): 238–249.
4. Raetz EA, Salzer WL. Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia, *Journal of Pediatric Hematology/Oncology*: October 2010 - Volume 32 - Issue 7 - p 554-563 doi: 10.1097/MPH.0b013e3181e6f003
5. Maese L, Rau RE, Raetz EA, et al. A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to *E. coli*-derived asparaginases. DOI: 10.1200/JCO.2020.38.15\_suppl.TPS7568 *Journal of Clinical Oncology* 38, no. 15\_suppl
6. Lin T, Hernandez-Illas M, Rey A, Jenkins J, et al. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant *Erwinia* Asparaginase (JZP-458) in Healthy Adult Volunteers. *Clin Transl Sci*. 2021 May;14(3):870-879. doi: 10.1111/cts.12947. Epub 2021 Mar 23.
7. Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. *Leuk Lymphoma* 2011;52:2237-2253.
8. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. NIH National Cancer Institute: Division of Cancer Treatment & Diagnosis – Cancer Therapy Evaluation Program. Available at:  
[https://ctep.cancer.gov/protocoldevelopment/electronic\\_applications/ctc.htm#ctc\\_50](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50).

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes
C83.57	Lymphoblastic (diffuse) lymphoma, spleen
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)

**RYLAZE™ (asparaginase erwinia chrysanthemi recombinant-rywn) Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2022, Magellan Rx Management

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction	Applicable State/US Territory	Contractor
15	KY, OH	CGS Administrators, LLC